Addex Therapeutics Files 6-K, Incorporates Press Release
Ticker: ADXN · Form: 6-K · Filed: Nov 12, 2024 · CIK: 1574232
Sentiment: neutral
Topics: regulatory-filing, press-release
TL;DR
Addex Therapeutics filed a 6-K on Nov 12, incorporating a Nov 11 press release into its F-3/S-8 filings.
AI Summary
Addex Therapeutics Ltd. filed a Form 6-K on November 12, 2024, reporting a press release issued on November 11, 2024. This filing is incorporated by reference into their existing registration statements on Form F-3 and Form S-8.
Why It Matters
This filing signals ongoing corporate communications and regulatory compliance for Addex Therapeutics, potentially impacting investor awareness of recent company developments.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release and does not contain new financial or operational information that would inherently increase risk.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- November 11, 2024 (date) — Date of press release
- November 12, 2024 (date) — Filing date
- Exhibit 99.1 (document) — Incorporated press release
- Form F-3 (Registration No. 333-255089) (document) — Registration statement
- Form S-8 (Registration No. 33 (document) — Registration statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on November 11, 2024, and incorporate it by reference into existing registration statements.
When was the press release that is being incorporated into this filing issued?
The press release was issued on November 11, 2024.
What are the registration statements into which this filing is incorporated by reference?
This filing is incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statement on Form S-8 (Registration No. 33).
What is the filing date of this Form 6-K?
This Form 6-K was filed on November 12, 2024.
What is the principal executive office address of Addex Therapeutics Ltd. as listed in the filing?
The principal executive office address is Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-11-12 06:05:04
Filing Documents
- f6k_111124.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-006203.txt ( ) — 14KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On November 11, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated November 11, 2024 INCORPORATION BY REFERENCE Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: November 11, 2024 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated November 11, 2024